(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol;(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 黄酮木脂素
• 英文名称: (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol;(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
• 化学式: C32H39NO15
• 分子量: 677.6
• InChiKey: XJCLWAHIAAEFAT-FUVGLPQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.0
• 重原子数：
  48
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  268
• 氢给体数：
  11
• 氢受体数：
  16

文献信息

• CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR, AND METHOD FOR ASSESSING OR SCREENING FOR SAME
  申请人：Link Genomics, Inc.

  公开号：EP3391883A1

  公开（公告）日：2018-10-24

  The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

  现有的 CNV 治疗药物仅仅是对症治疗的药物，人们强烈需要根治性的治疗药物。同样，干性老年黄斑变性的治疗药物也不存在，人们对根治性治疗药物的需求非常强烈。本发明提供了一种脉络膜新生血管的预防和/或治疗药物，其活性成分含有一种具有抑制视网膜色素上皮细胞上皮-间质转化活性的化合物。此外，本发明还提供了一种色素沉着抑制剂，其活性成分是一种具有抑制视网膜色素上皮细胞上皮-间质转化活性的化合物。
• CHOROIDAL NEOVASCULARIZATION SUPPRESSOR OR DRUSEN FORMATION SUPPRESSOR
  申请人：Link Genomics, Inc.

  公开号：EP3750540A1

  公开（公告）日：2020-12-16

  The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

  现有的 CNV 治疗药物仅仅是对症治疗的药物，人们强烈需要根治性的治疗药物。同样，干性老年黄斑变性的治疗药物也不存在，人们对根治性治疗药物的需求非常强烈。本发明提供了一种脉络膜新生血管的预防和/或治疗药物，其活性成分含有一种具有抑制视网膜色素上皮细胞上皮-间质转化活性的化合物。此外，本发明还提供了一种色素沉着抑制剂，其活性成分是一种具有抑制视网膜色素上皮细胞上皮-间质转化活性的化合物。
• Silybin injection and preparation method therefor
  申请人：TASLY PHARMACEUTICAL GROUP CO., LTD.

  公开号：US10314923B2

  公开（公告）日：2019-06-11

  A silybin injection contains silybin, sulfobutyl ether-β-cyclodextrin, an organic solvent for injection, a pH regulator, and may further contain a co-solvent, a lyophilization bulking agent, and water for injection.

  水飞蓟宾注射液含有水飞蓟宾、磺丁基醚-β-环糊精、注射用有机溶剂、pH 值调节剂，还可能含有助溶剂、冻干膨松剂和注射用水。
• Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same
  申请人：Link Genomics, Inc.

  公开号：US10761087B2

  公开（公告）日：2020-09-01

  The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

  现有的 CNV 治疗药物仅仅是对症治疗的药物，人们强烈需要根治性的治疗药物。同样，干性老年黄斑变性的治疗药物也不存在，人们对根治性治疗药物的需求非常强烈。本发明提供了一种脉络膜新生血管的预防和/或治疗药物，其活性成分含有一种具有抑制视网膜色素上皮细胞上皮-间质转化活性的化合物。此外，本发明还提供了一种色素沉着抑制剂，其活性成分是一种具有抑制视网膜色素上皮细胞上皮-间质转化活性的化合物。
• SILYBIN INJECTION AND PREPARATION METHOD THEREFOR
  申请人：Tasly Pharmaceutical Group Co., Ltd.

  公开号：EP3243512B1

  公开（公告）日：2021-09-15